RE: 80p+16 Apr 2020 13:09
‘Sticky fingers’ not sure I agree. There have been three insti’s selling since the half year report. The BoD have been admirably candid in their trading statement that some of the products are not being taken up by the market as quickly as they would hope. They are running on fumes for cash and could really do with down payments from the DoD to see them through.
From my experience off the back of an excellent sp rise an AIM company does not usually wait to run out of cash before they raise. Loo, sorry if that’s not what you want to hear but it’s in the RNS’s. Likewise they have an excellent product in the Genedrive platform that imo will deliver an unmet need and possibly even dent NCYT as many investors may shift. I can see it in in use in many health centres, military clinics even in use by football physio’s, who knows. But they are in a perceived race with AVCT, although my view is there is plenty of room in the market and both as the products are slightly different, but that is not always how it plays out on AIM.
To run the race and meet the regulatory and compliance needs they need cash. It’s no point in delaying that decision. I expect an accelerated bookbuild in the next couple of weeks once the break is out the way and I suspect some of the selling has been done in anticipation and there is probably money on the sidelines waiting for it to be done.
I am willing to invest once they are cashed up, other posters can blame the market maker and shout, you wouldn’t wanna be and £1.50 here we come. Each to their own, it’s a democracy but let’s see what the next couple of weeks brings and then you can add ‘it’s oversubscribed’ to the list of sycophantic chants!
Trek
Sign In
Follow the stocks
